Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Abstract Background Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) every week or every other week and prednisone tapering achieved superior rates of sustained remission to patients treated with placebo and prednisone tapering in a randomised controlled trial. Health-related...

Full description

Bibliographic Details
Main Authors: Vibeke Strand, Sophie Dimonaco, Katie Tuckwell, Micki Klearman, Neil Collinson, John H. Stone
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Arthritis Research & Therapy
Subjects:
DMARDs (biologic)
Inflammation
Giant cell arteritis
Patient-reported outcomes
Quality of life
Tocilizumab
Online Access:http://link.springer.com/article/10.1186/s13075-019-1837-7

Internet

http://link.springer.com/article/10.1186/s13075-019-1837-7

Similar Items